PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 6, 2009Journal of Cardiovascular Electrophysiology32 citations

Triple‐Site Versus Standard Cardiac Resynchronization Therapy Study (TRUST CRT): Clinical Rationale, Design, and Implementation

View Full Paper
RLRadosław LenarczykOKOskar KowalskiBŚBeata Średniawa

Key Result

The TRUST CRT trial is designed to evaluate triple-site versus standard cardiac resynchronization therapy in 100 patients with heart failure; results are not reported in this design paper.

Study Design

Type

RCT (n=100)

Blinding

Single-blind

Randomization

1:1

Multicenter

No

Structured PICO

Does triple-site CRT-D improve clinical and functional outcomes compared to standard CRT-D in patients with moderate to severe heart failure and mechanical dyssynchrony?

P
Population
100 patients with moderate to severe heart failure, LV dysfunction, mechanical dyssynchrony, wide QRS, and sinus rhythm, followed for at least 6 months.
I
Intervention
Triple-site cardiac resynchronization therapy with defibrillator (CRT-D)
C
Comparator
Standard cardiac resynchronization therapy with defibrillator (CRT-D)
O
Outcome
6-month combined endpoint of alive status, freedom from hospitalization for HF or heart transplantation, relative ≥10% increase in LV ejection fraction, ≥10% increase in peak oxygen consumption, and ≥10% increase in 6-minute walking distancecomposite

The TRUST CRT trial is designed to evaluate whether triple-site pacing offers superior clinical and functional benefits over standard cardiac resynchronization therapy in patients with moderate to severe heart failure.

Abstract

BACKGROUND: Cardiac resynchronization therapy (CRT) reduces morbidity and mortality in patients with heart failure (HF), lowered LV ejection fraction, and wide QRS. However, many patients ( or =120 ms, sinus rhythm, LV dysfunction (EF or =10% increase in LV ejection fraction, > or =10% in peak oxygen consumption, and > or =10% in 6-minute walking distance. METHODS: Patients with HF receiving optimal pharmacotherapy, with LV dysfunction, mechanical dyssynchrony, wide QRS and sinus rhythm will be randomized in a 1: 1 fashion to standard or triple-site CRT-D. Patients will be followed for 1 week, 1, 3, and 6 months during a blind phase, then every 6 months until study completion. One hundred patients will be enrolled by the study center. CONCLUSIONS: TRUST CRT is a randomized, clinical trial in CRT candidates to evaluate the effectiveness of triple-site pacing versus standard resynchronization in patients with HF.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lenarczyk et al. (2009) conducted an RCT in Heart failure (n=100). Triple-site CRT-D vs. Standard CRT-D was evaluated on 6-month combined endpoint of alive status, freedom from hospitalization for HF or heart transplantation, relative ≥10% increase in LV ejection fraction, ≥10% in peak oxygen consumption, and ≥10% in 6-minute walking distance. The TRUST CRT trial is designed to evaluate triple-site versus standard cardiac resynchronization therapy in 100 patients with heart failure; results are not reported in this design paper.

synapsesocial.com/papers/6a6bccb13a414fea3bf2b597https://doi.org/10.1111/j.1540-8167.2008.01394.x
Ask AI
Helpful
Bookmark
Share
View Full Paper